Randomized Clinical Trial to Evaluate the Effect of Canephron N in Comparison to Ciprofloxacin in the Prevention of Postoperative Lower Urinary Tract Infections after Midurethral Sling Surgery
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
Urinary tract infections (UTIs) are one of the most common reasons for antibiotic prescriptions among women worldwide. UTIs are also associated with intra- and postoperative catheterization, which is an essential component of many gynecological surgical procedures, including midurethral sling (MUS) placement.
The aim of this study was to compare the incidence of UTI subsequent to a MUS procedure.
The study involved 562 female patients who underwent MUS procedures due to stress urinary incontinence (SUI). Patients were assigned in a 1:1 ratio to two study groups: patients receiving 500 mg of ciprofloxacin three times a day for 3 consecutive days after surgery or patients receiving 5 mL of Canephron taken orally three times a day for 3 weeks.
After analyzing the collected data, it was found that in the group of patients receiving ciprofloxacin, 29 women (10.98 %) had a UTI, whereas in the group of patients receiving Canephron, 36 women (13.64 %) had a UTI within 6 months after the patient’s MUS procedure. No statistically significant difference between the two groups was noted. Postoperative prophylaxis with a phytodrug can be perceived as an attractive option in the reduction of antibiotic consumption among female patients after a MUS procedure.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Foxman, B. Recurring urinary tract infection: Incidence and risk factors. Am. J. Public Health 1990; 80, 331–333.
Available online: https://www.who.int/news-room/fact-sheets/detail/antibioticresistance (accessed on 28 August 2020).
Stamm, W.E. Urinary Tract Infections, 4th ed.; Bennett, J.V., Brachman, P.S., Eds.; Lippincott-Raven: Philadelphia, PA, USA, 1998; pp. 477–483.
Foxman, B. Urinary tract infection syndromes: Occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect. Dis. Clin. N. Am. 2014, 28, 11–13.
Lo, E.; Nicolle, L.; Classen, D.; Arias, K.M.; Podgorny, K.; Anderson, D.J.; Burstin, H.; Calfee, D.P.; Coffin, S.E.; Dubberke, E.R.; et al. Strategies to prevent catheter associated urinary tract infections in acute care hospitals. Infect. Cont. Hosp. Epid. 2008, 29, S41–S50.
Crowe, H.; Clift, R.; Duggan, G.; Bolton, D.; Costello, A. Randomised study of the effect of midnight removal of urinary catheters. Urol. Nurs. 1994, 14, 18–20.
Kamilya, G.; Seal, S.L.; Mukherji, J.; Bhattacharyya, S.K.; Hazra, A. A randomized controlled trial comparing short versus long-term catheterization after uncomplicated vaginal prolapse surgery. J. Obstet. Gynaecol. Res. 2010, 36, 154–158.
Foxman, B.; Cronenwett, A.E.W.; Spino, C.; Berger, M.B.; Morgan, D.M. Cranberry juice capsules and urinary tract infection after surgery: Results of a randomized trial. Am. J. Obstet. Gynecol. 2015, 213, 194.e1.
Jonsson Funk, M.; Levin, P.J.; Wu, J.M. Trends in the surgical management of stress urinary incontinence. Obstet. Gynecol. 2012, 119, 845–851.
Tew, L.; Pomfret, I.; King, D. Infection risks associated with urinary catheters. Nurs. Stand. 2005, 20, 55–61.
Tambyah, P.A.; Halvorson, K.T.; Maki, D.G. A prospective study of pathogenesis of catheter associated urinary tract infections. Mayo Clin. Proc. 1999, 74, 131–136.
Saint, S.; Greene, M.T.; Krein, S.L.; Rogers, M.A.; Ratz, D.; Fowler, K.E.; Edson, B.S.; Watson, S.R.; Meyer-Lucas, B.; Masuga, M.; et al. A program to prevent catheter-associated urinary tract infection in acute care. N. Engl. J. Med. 2016, 374, 2111–2119.
Singh, R.; Hokenstad, E.D.;Wiest, S.R.; Kim-Fine, S.;Weaver, A.L.; McGree, M.E.; Klingele, C.J.; Trabuco, E.C.; Gebhart, J.B. Randomized controlled trial of silver-alloy-impregnated suprapubic catheters versus standard suprapubic catheters in assessing urinary tract infection rates in urogynecology patients. Int. Urogynecol. J. 2019, 30, 779–787.
Milan, P.B.; Ivan, I.M. Catheter-associated and nosocomial urinary tract infections: Antibiotic resistance and influence on commonly used antimicrobial therapy. Int. Urol. Nephrol. 2009, 41, 461–464.
Naber, K.G. Efficacy and safety of the phytotherapeutic drug Canephron® N in prevention and treatment of urogenital and gestational disease: Review of clinical experience in EasternEurope and Central Asia. Res. Rep. Urol. 2013, 5, 39–46.
Künstle, G.; Brenneis, C.; Haunschild, J. Efficacy of Canephron® N against bacterial adhesion, inflammation and bladder hyperactivity. Eur. Urol. Suppl. 2013, 12, e671.
Künstle, G.; Brenneis, C.; Pergola, C.;Werz, O.; Haunschild, J. Anti-inflammatory effects of Canephron® N and effectiveness in a model of interstitial cystitis. Urologe 2013, 52 (Suppl. S1), e97.
Marcon, J.; Schubert, S.; Stief, C.G.; Magistro, G. In vitro efficacy of phytotherapeutics suggested for prevention and therapy of urinary tract infections. Infection 2019, 47, 937–944.
Nausch, B.; Pace, S.; Pein, H.; Koeberle, A.; Rossi, A.; Künstle, G.; Werz, O. The standardized herbal combination BNO 2103 contained in Canephron® N alleviates inflammatory pain in experimental cystitis and prostatitis. Phytomedicine 2019, 60, 152987.
Miotla, P.;Wawrysiuk, S.; Naber, K.;Markut-Miotla, E.; Skorupski, P.; Skorupska, K.; Rechberger, T. Should We Always Use Antibiotics after Urodynamic Studies in High-Risk Patients? Biomed. Res. Int. 2018, 2018, 1607425.
Wagenlehner, F.M.; Abramov-Sommariva, D.; Höller, M.; Steindl, H.; Naber, K.G. Non-Antibiotic Herbal Therapy (BNO 1045) versus Antibiotic Therapy (Fosfomycin Trometamol) forthe Treatment of Acute Lower Uncomplicated Urinary Tract Infections inWomen: A Double-Blind, Parallel-Group, Randomized, Multicentre, Non-Inferiority Phase III Trial. Urol. Int. 2018, 101, 327–336.
Rechberger, T.; Futyma, K.; Jankiewicz, K.; Adamiak, A.; Bogusiewicz, M.; Bartuzi, A.; Miotła, P.; Skorupski, P.; Tomaszewski, J. Tape fixation: An important surgical step to improve success rate of anti-incontinence surgery. J. Urol. 2011, 186, 180–184.
Kelleher, C.J.; Cardozo, L.D.; Khullar, V.; Salvatore, S. A new questionnaire to assess the quality of life of urinary incontinent women. Br. J. Obstet. Gynaecol. 1997, 104, 1374–1379.
Shumaker, S.A.;Wyman, J.F.; Uebersax, J.S.; McClish, D.; Fantl, J.A. Health related quality of life measures for women with urinary incontinence: The urogenital distress inventory and the incontinence impact questionnaire. Qual. Life Res. 1994, 3, 291–306.
Uebersax, J.S.; Wyman, J.F.; Shumaker, S.A.; McClish, D.K.; Fantl, J.A. Short forms to assess life quality symptom distress for urinary incontinence in women: The incontinence impact questionnaire and the urogenital distress inventory. Neurourol. Urodyn. 1995, 14, 131–139.
Faul, F.; Erdfelder, E.; Lang, A.G.; Buchner, A. G Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods 2007, 39, 175–191.
Skorupska, K.; Rechberger, T.; Bogusiewicz, M.; Adamiak-Godlewska, A.; Kwiatkowska, A.; Miotla, P. Current trends in urogynecological surgeries in Poland. Int. Urogynecol. J. 2020, 31, 1627–1632.
Marschall, J.; Carpenter, C.R.; Fowler, S.; Trautner, B.W. CDC Prevention Epicenters Program. Antibiotic Prophylaxis for Urinary Tract Infections After Removal of Urinary Catheter: Meta-Analysis. BMJ 2013, 346, f3147.
Davidov, M.I.; Bunova, N.E. Comparative assessment of Canephron N and ciprofloxacin as monotherapy of acute uncomplicated cystitis in women. Urologiia 2018, 4, 24–32.
Savas, L.; Guvel, S.; Onlen, Y.; Savas, N.; Duran, N. Nosocomial urinary tract infections: Microorganisms, antibiotic sensitivities and risk factors. West Indian Med. J. 2006, 55, 188–193.
Dudeck, M.A.; Horan, T.C.; Peterson, K.D.; Allen-Bridson, K.; Morrell, G.; Anttila, A.; Pollock, D.A.; Edwards, J.R. National Healthcare Safety Network (NHSN) report, data summary for 2011, device-associated module. Am. J. Infect. Control 2013, 41, 286–300.
Stewart, L.E.; Hall, E.; Carberry, C.L. Cystoscopy at the time of incontinence and prolapse surgery. Curr. Opin. Obstet. Gynecol. 2018, 30, 441–445.
Falagas, M.E.; Athanasiou, S.; Iavazzo, C.; Tokas, T.; Antsaklis, A. Urinary tract infections after pelvic floor gynecological surgery: Prevalence and effect of antimicrobial prophylaxis. A systematic review. Int. Urogynecol. J. Pelvic. Floor. Dysfunct. 2008, 19, 1165–1172.
Glavind, K.; Morup, L.; Madsen, H.; Glavind, J. A prospective, randomised, controlled trial comparing 3 hour and 24 hour postoperative removal of bladder catheter and vaginal pack following vaginal prolapse surgery. Acta Obstet. Gynecol. Scand. 2007, 86, 1122–1125.
Foon, R.; Toozs-Hobson, P.; Latthe, P. Prophylactic antibiotics to reduce the risk of urinary tract infections after urodynamic studies. Cochrane Database Syst. Rev. 2012, 10, CD008224.
Naber, K.G.; Bonkat, G.; Wagenlehner, F.M.E. The EAU and AUA/CUA/SUFU Guidelines on Recurrent Urinary Tract Infections: What is the Difference? Eur. Urol. 2020, 29, S0302-2838(20)30461-9.
Carapeti, E.A.; Andrews, S.M.; Bentley, P.G. Randomised study of sterile versus non sterile urethral catheterisation. Ann. R. Coll. Surg. Engl. 1996, 78, 59–60.
Nickel, J.C.; Feero, P.; Costerton, J.W.;Wilson, E. Incidence and importance of bacteriuria in postoperative, short-term urinary catheterization. Can. J. Surg. 1989, 32, 131–132.
